The first research criteria for FTD “Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups,” was developed in 1994. The clinical diagnostic criteria were revised in the late 1990s, when the FTD spectrum was divided into a behavioral variant, a nonfluent aphasia variant and a semantic dementia variant. The most recent revision of the clinical research criteria was by  International Behavioural Variant FTD Criteria Consortium (FTDC) in 2011.

Notable cases
Notable cases of bvFTD when mostly were referred to as Picks disease. John Berry (1963-2016), American hardcore punk musician and founding member of the Beastie Boys. Don Cardwell (1935–2008), Major League Baseball pitcher
Charmian Carr (1942–2016), who played Liesl, from the Sound of Music, born Charmian Anne Farnon. Jerry Corbetta (1947–2016), frontman, organist and keyboardist of American psychedelic rock band Sugarloaf
Ted Darling (1935–1996), Buffalo Sabres television announcer
Robert W. Floyd (1936–2001), computer scientist
Lee Holloway (born 1981), co-founder of Cloudflare
Colleen Howe (1933–2009), sports agent and hockey team manager, known as "Mrs. Hockey"
Kazi Nazrul Islam (1899–1976), notable Bengali poet and National Poet of Bangladesh
Ralph Klein (1942–2013), former premier of Alberta, Canada
Terry Jones (1942-2020), Welsh comedian (Monty Python) and director.
Paricalcitol (chemically it is 19-nor-1,25-(OH)2-vitamin D2. Marketed by Abbott Laboratories under the trade name Zemplar) is a drug used for the prevention and treatment of secondary hyperparathyroidism (excessive secretion of parathyroid hormone) associated with chronic kidney failure. It is an analog of 1,25-dihydroxyergocalciferol, the active form of vitamin D2 (ergocalciferol). It was patented in 1989 and approved for medical use in 1998. Medical uses
Its primary use in medicine is in the treatment of secondary hyperparathyroidism associated with chronic kidney disease. However current evidence is not sufficient to demonstrate an advantage of paricalcitol over non-selective vitamin D derivatives for this indication. Adverse effects
Adverse effects by frequency:Very common (>10% frequency):

NauseaCommon (1-10% frequency):

Uncommon (0.1-1% frequency):

‡ These are adverse effects only seen in patients with grade 3 or 4 chronic kidney disease. † These are adverse effects only seen in patients with grade 5 chronic kidney disease. Contraindications
Contraindications include:
Vitamin D intoxication
Hypercalcaemia
Hypersensitivity to paricalcitol or any of its excipientswhereas cautions include:
Impaired liver function
It is also advised that physicians regularly monitor their patients calcium and phosphorus levels. Interactions
Drugs that may interact with paricalcitol include:

Overdose
Electrolyte abnormalities (e.g. hypercalcaemia and hyperphosphataemia) are common overdose symptoms. Treatment is mostly supportive, with particular attention being paid to correcting electrolyte anomalies and reducing intake of calcium in both the form of supplementation and diet.